...
arct-img

Arcturus Therapeutics Holdings Inc, Common Stock

ARCT

NMQ

$15.72

-$0.01

(-0.06%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$426.08M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
47.25K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$14.93 L
$45 H
$15.72

About Arcturus Therapeutics Holdings Inc, Common Stock

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameARCTSectorS&P500
1-Week Return-14.32%-3.39%0.2%
1-Month Return-3.32%-1.92%2.72%
3-Month Return-25.13%-10.54%7.31%
6-Month Return-44.08%-4.47%10.44%
1-Year Return-45.13%4.06%27.53%
3-Year Return-66.56%0.94%30.88%
5-Year Return38.22%36.67%89.21%
10-Year Return-41.17%102.87%199.95%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue20.79M9.54M12.36M205.75M157.75M[{"date":"2019-12-31","value":10.1,"profit":true},{"date":"2020-12-31","value":4.64,"profit":true},{"date":"2021-12-31","value":6.01,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":76.67,"profit":true}]
Cost of Revenue32.44M55.95M171.86M143.05M2.96M[{"date":"2019-12-31","value":18.88,"profit":true},{"date":"2020-12-31","value":32.55,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.24,"profit":true},{"date":"2023-12-31","value":1.72,"profit":true}]
Gross Profit(11.65M)(46.41M)(159.50M)62.70M154.79M[{"date":"2019-12-31","value":-7.53,"profit":false},{"date":"2020-12-31","value":-29.98,"profit":false},{"date":"2021-12-31","value":-103.04,"profit":false},{"date":"2022-12-31","value":40.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(56.04%)(486.50%)(1290.57%)30.48%98.13%[{"date":"2019-12-31","value":-57.11,"profit":false},{"date":"2020-12-31","value":-495.79,"profit":false},{"date":"2021-12-31","value":-1315.22,"profit":false},{"date":"2022-12-31","value":31.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses46.30M81.06M215.21M193.58M235.95M[{"date":"2019-12-31","value":19.62,"profit":true},{"date":"2020-12-31","value":34.36,"profit":true},{"date":"2021-12-31","value":91.21,"profit":true},{"date":"2022-12-31","value":82.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(25.51M)(71.52M)(202.85M)12.18M(78.20M)[{"date":"2019-12-31","value":-209.52,"profit":false},{"date":"2020-12-31","value":-587.37,"profit":false},{"date":"2021-12-31","value":-1665.86,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-642.24,"profit":false}]
Total Non-Operating Income/Expense(924.00K)(985.00K)(2.74M)(1.95M)61.05M[{"date":"2019-12-31","value":-1.51,"profit":false},{"date":"2020-12-31","value":-1.61,"profit":false},{"date":"2021-12-31","value":-4.49,"profit":false},{"date":"2022-12-31","value":-3.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(25.99M)(72.15M)(203.67M)10.64M(27.89M)[{"date":"2019-12-31","value":-244.18,"profit":false},{"date":"2020-12-31","value":-677.83,"profit":false},{"date":"2021-12-31","value":-1913.51,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-262.03,"profit":false}]
Income Taxes(270.00K)(784.00K)3.19M1.29M1.83M[{"date":"2019-12-31","value":-8.47,"profit":false},{"date":"2020-12-31","value":-24.58,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":40.61,"profit":true},{"date":"2023-12-31","value":57.54,"profit":true}]
Income After Taxes(25.72M)(71.36M)(206.86M)9.35M(29.73M)[{"date":"2019-12-31","value":-275.12,"profit":false},{"date":"2020-12-31","value":-763.33,"profit":false},{"date":"2021-12-31","value":-2212.68,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-317.95,"profit":false}]
Income From Continuous Operations(25.99M)(72.15M)(203.67M)9.35M99.33M[{"date":"2019-12-31","value":-26.17,"profit":false},{"date":"2020-12-31","value":-72.64,"profit":false},{"date":"2021-12-31","value":-205.05,"profit":false},{"date":"2022-12-31","value":9.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(25.72M)(71.36M)(206.86M)9.35M(29.73M)[{"date":"2019-12-31","value":-275.12,"profit":false},{"date":"2020-12-31","value":-763.33,"profit":false},{"date":"2021-12-31","value":-2212.68,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-317.95,"profit":false}]
EPS (Diluted)(2.04)(3.39)(7.74)0.34(1.04)[{"date":"2019-12-31","value":-600,"profit":false},{"date":"2020-12-31","value":-997.06,"profit":false},{"date":"2021-12-31","value":-2276.47,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-305.88,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARCT
Cash Ratio 3.41
Current Ratio 4.76

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARCT
ROA (LTM) -12.15%
ROE (LTM) -23.12%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARCT
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARCT
Trailing PE NM
Forward PE 2.48
P/S (TTM) 2.66
P/B 1.68
Price/FCF NM
EV/R 1.63
EV/Ebitda NM

FAQs

What is Arcturus Therapeutics Holdings Inc share price today?

Arcturus Therapeutics Holdings Inc (ARCT) share price today is $15.72

Can Indians buy Arcturus Therapeutics Holdings Inc shares?

Yes, Indians can buy shares of Arcturus Therapeutics Holdings Inc (ARCT) on Vested. To buy Arcturus Therapeutics Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARCT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arcturus Therapeutics Holdings Inc be purchased?

Yes, you can purchase fractional shares of Arcturus Therapeutics Holdings Inc (ARCT) via the Vested app. You can start investing in Arcturus Therapeutics Holdings Inc (ARCT) with a minimum investment of $1.

How to invest in Arcturus Therapeutics Holdings Inc shares from India?

You can invest in shares of Arcturus Therapeutics Holdings Inc (ARCT) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARCT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arcturus Therapeutics Holdings Inc shares
What is Arcturus Therapeutics Holdings Inc 52-week high and low stock price?

The 52-week high price of Arcturus Therapeutics Holdings Inc (ARCT) is $45. The 52-week low price of Arcturus Therapeutics Holdings Inc (ARCT) is $14.93.

What is Arcturus Therapeutics Holdings Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Arcturus Therapeutics Holdings Inc (ARCT) is

What is Arcturus Therapeutics Holdings Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arcturus Therapeutics Holdings Inc (ARCT) is 1.68

What is Arcturus Therapeutics Holdings Inc dividend yield?

The dividend yield of Arcturus Therapeutics Holdings Inc (ARCT) is 0.00%

What is the Market Cap of Arcturus Therapeutics Holdings Inc?

The market capitalization of Arcturus Therapeutics Holdings Inc (ARCT) is $426.08M

What is Arcturus Therapeutics Holdings Inc’s stock symbol?

The stock symbol (or ticker) of Arcturus Therapeutics Holdings Inc is ARCT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top